T cells in amyotrophic lateral sclerosis

The inflammatory process in ALS involves infiltration of T cells and activation of antigen presenting cells co‐localizing with motor neuron damage in the brain and spinal cord. The role of T cells in the pathogenic process is not settled. T cells may damage motor neurons by cell‐cell contact or cytokine secretion, or contribute indirectly to motor neuron damage through activation of microglia and macrophages. Alternatively, T cell infiltration may be an epiphenomenon related to clearance of dead motor neurons. Lessons from animal models of neuroinflammation and neurodegeneration have shown that T cell responses can be neuroprotective or even enhance neurogenesis. Therefore, it is possible that T cells can be induced to slow motor neuron destruction and facilitate repair in ALS. The T cell modulating drug glatiramer acetate has shown promising results in animal models, and is being currently investigated in a phase II trial in ALS. This paper reviews the evidence for T cells as pathogenic players and therapeutic targets in ALS.

[1]  E. Agranov,et al.  Autoimmune T cells as potential neuroprotective therapy for spinal cord injury , 2000, The Lancet.

[2]  Z. Stelmasiak,et al.  Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. , 2002, Cytokine.

[3]  K. Morrison,et al.  Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment , 2006, Expert Reviews in Molecular Medicine.

[4]  D. Troost,et al.  Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis , 1990, Neuropathology and applied neurobiology.

[5]  F. Picard,et al.  T‐cell receptor Vβ gene usage in CSF lymphocytes in X‐linked adrenoleukodystrophy , 2005 .

[6]  H. Mitsumoto,et al.  Randomized controlled phase II trial of glatiramer acetate in ALS , 2006, Neurology.

[7]  P. Bretscher,et al.  A two-step, two-signal model for the primary activation of precursor helper T cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Neumann,et al.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases , 2002, Trends in Neurosciences.

[9]  Kathryn J. Jones,et al.  Brain-derived neurotrophic factor supports facial motoneuron survival after facial nerve transection in immunodeficient mice , 2005, Brain, Behavior, and Immunity.

[10]  H. Vinters,et al.  Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[11]  P. Kushner,et al.  Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[12]  P. Mcgeer,et al.  Expression of the histocompatibility glycoprotein HLA-DR in neurological disease , 2004, Acta Neuropathologica.

[13]  H. Lassmann,et al.  Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. , 1990, The American journal of pathology.

[14]  L. Defebvre,et al.  Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? , 2005, Neurology.

[15]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[16]  G. Galbraith A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2008 .

[17]  D. Gajdusek,et al.  Cellular immunity in Guamanians with amyotrophic lateral sclerosis and Parkinsonism-dementia. , 1978, The New England journal of medicine.

[18]  A. Begovich,et al.  T Cell Receptor BV Gene Rearrangements in the Spinal Cords and Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis , 1999, Neurobiology of Disease.

[19]  M. McGrath,et al.  Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) , 2005, Journal of Neuroimmunology.

[20]  Frauke Zipp,et al.  Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL , 2005, Neuron.

[21]  S. Romagnani,et al.  T-cell subsets (Th1 versus Th2). , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  H. Wekerle Breaking ignorance: the case of the brain. , 2006, Current topics in microbiology and immunology.

[23]  L. Jones,et al.  Lymphocyte infiltration in the injured brain: Role of proinflammatory cytokines , 2003, Journal of neuroscience research.

[24]  F. Zipp,et al.  Neuronal damage in brain inflammation. , 2007, Archives of neurology.

[25]  A. Mildner,et al.  Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes , 2007, Nature Genetics.

[26]  Irun R. Cohen,et al.  Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy , 1999, Nature Medicine.

[27]  V. Perry,et al.  What is immune privilege (not)? , 2007, Trends in immunology.

[28]  S. Rivest,et al.  Neuroprotective role of the innate immune system by microglia , 2007, Neuroscience.

[29]  P. Mcgeer,et al.  Inflammatory processes in amyotrophic lateral sclerosis , 2002, Muscle & nerve.

[30]  H. Neumann Control of glial immune function by neurons , 2001, Glia.

[31]  M. Schwartz,et al.  Protective autoimmunity: interferon‐γ enables microglia to remove glutamate without evoking inflammatory mediators , 2005, Journal of neurochemistry.

[32]  Yaniv Ziv,et al.  Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood , 2006, Nature Neuroscience.

[33]  H. Gendelman,et al.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. , 2007, Journal of leukocyte biology.

[34]  A. Nagai,et al.  Cytokines, chemokines, and cytokine receptors in human microglia , 2002, Journal of neuroscience research.

[35]  Kathryn J. Jones,et al.  Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4+ T cells , 2006, Experimental Neurology.

[36]  H. Gendelman,et al.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease , 2007 .

[37]  Yaniv Ziv,et al.  Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells , 2006, Molecular and Cellular Neuroscience.

[38]  E. Hauben,et al.  Neuronal Survival after CNS Insult Is Determined by a Genetically Encoded Autoimmune Response , 2001, The Journal of Neuroscience.

[39]  M. Schwartz,et al.  Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: A dialogue with microglia , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E. Yoles,et al.  Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Holmøy,et al.  ALS: Cytokine profile in cerebrospinal fluid T‐cell clones , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[42]  H. Moser,et al.  Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy , 1985, Annals of neurology.

[43]  H. Gendelman,et al.  Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS , 2007, Neurobiology of Disease.

[44]  J. Niland,et al.  Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases , 1998, Journal of the Neurological Sciences.

[45]  L A Wheeler,et al.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Defebvre,et al.  Elevated IL-6 and TNF-α levels in patients with ALS: Inflammation or hypoxia? , 2005, Neurology.

[47]  W. Hickey Migration of Hematogenous Cells Through the Blood‐Brain Barrier and the Initiation of CNS Inflammation , 1991, Brain pathology.

[48]  Kuixing Zhang,et al.  Whole-genome analysis of sporadic amyotrophic lateral sclerosis. , 2007, The New England journal of medicine.

[49]  D. Rowe,et al.  Interleukin‐12 and interferon‐γ are not detectable in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[50]  R. Hohlfeld Neurotrophic cross-talk between the nervous and immune systems: Relevance for repair strategies in multiple sclerosis? , 2008, Journal of the Neurological Sciences.

[51]  H. Nyland,et al.  T lymphocytes in peripheral blood from patients with neurological diseases , 1978, Acta neurologica Scandinavica.

[52]  Lawrence Steinman,et al.  A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell–mediated tissue damage , 2007, Nature Medicine.

[53]  E. Hauben,et al.  Morphological aspects of spinal cord autoimmune neuroprotection: colocalization of T cells with B7--2 (CD86) and prevention of cyst formation. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  A. Rombos,et al.  RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[55]  Shimon Sakaguchi,et al.  Natural regulatory T cells: mechanisms of suppression. , 2007, Trends in molecular medicine.

[56]  J. Kira,et al.  Increased IL-13-producing T cells in ALS: Positive correlations with disease severity and progression rate , 2007, Journal of Neuroimmunology.

[57]  T. Ziemssen,et al.  Glatiramer acetate: mechanisms of action in multiple sclerosis. , 2007, International review of neurobiology.

[58]  Martin Kerschensteiner Strategies for axonal repair in central nervous system diseases , 2007, Journal of Neurology.

[59]  P. Mcgeer,et al.  Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. , 1992, The American journal of pathology.

[60]  H. Waldmann,et al.  The window of therapeutic opportunity in multiple sclerosis , 2005, Journal of Neurology.

[61]  H. Hartung,et al.  Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS , 2007, Experimental Neurology.

[62]  S. Appel,et al.  Immune reactivity in a mouse model of familial ALS correlates with disease progression , 2001, Neurology.

[63]  H. Gendelman,et al.  CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2007, Journal of Neuroimmunology.

[64]  Z. Sučić,et al.  Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. , 2002, Cytokine.

[65]  D. Troost,et al.  Lymphocytic infiltration in the spinal cord of patients with amyotrophic lateral sclerosis. , 1989, Clinical neuropathology.

[66]  H. Neumann,et al.  Induction of MHC class I genes in neurons. , 1995, Science.

[67]  F. Zipp,et al.  Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue , 2004, The Journal of Neuroscience.

[68]  J. Tajti,et al.  Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. , 1993, Archives of neurology.